Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), sometimes
referred to as the novel coronavirus (2019-nCoV), is currently a worldwide threat to public health.
According to the Johns Hopkins University monitor (available at, coronavirus.jhu.edu/map), there have
been more than 10 million reported cases of coronavirus 2019 disease (COVID-19) and 500,000 deaths
as of June 29, 2020, deeming urgent the identification of a drug candidate and treatment regimen.
Objective: This work aims to compile the current knowledge available on this drug, including its background,
approved uses, some synthetic methods, the primary pharmacological aspects, the results
against COVID-19 reported so far, and ongoing clinical trials against COVID-19.
Methods: We reviewed relevant press releases, scientific articles, and official documents to compile information
Results: We highlight, in a clear and concise form, not only the published and ongoing clinical trials on
the use of Favipiravir against COVID-19 but also compile some relevant synthetic and pharmacological
information available about this drug.
Conclusion: The Antiviral Favipiravir has shown interesting preliminary results, but it seems too early
to recommend a treatment protocol for COVID-19 based on this drug. Robust clinical trials that will
provide less biased data on its efficacy and safety are being pushed forward by FUJIFILM Corporation
and by research groups around the globe.